Biocept Launches Proprietary Liquid Biopsy Test to Detect RET Fusions in Patients with Lung Cancer
Genetic alterations RET and ROS1 genes were identified in patients with non-small cell lung cancer (NSCLC). In initial screening studies using a variety of genotyping techniques, RET and ROS1 rearrangements were each reported in 1-2% of patients with NSCLC. Patients with either RET or ROS1 rearrangements appear to have unique clinical and pathologic features that may facilitate identification and enrichment strategies. These features may in turn expedite enrollment in clinical trials evaluating genotype-directed therapies, such as tyrosine kinase inhibitors, in these rare patient populations. In 2015,
"The discovery of RET and ROS1 chromosomal rearrangements involving specific genes in patients with NSCLC has stimulated interest in developing therapies that specifically target these oncogenic fusions," said
"Just like ALK fusions are targeted by Crizotinib, leading to improvements in patients with ALK+ lung cancer, information on RET fusions can provide similar benefits to RET targeted agents," said
More than 220,000 new cases of lung cancer are reported year in the
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the detection
and treatment of cancer, the role of androgen receptor expression in personalized medicine and its prognostic and predictive value, our impact on diagnostic strategies, our ability to enhance individual cancer treatments and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-launches-proprietary-liquid-biopsy-test-to-detect-ret-fusions-in-patients-with-lung-cancer-300271131.html
SOURCE
News Provided by Acquire Media